Mosanna Therapeutics Launches Novel Nasal Spray for Sleep Apnea with $80 Million Backing
Deal News | Jun 09, 2025 | Broadview Ventures
Mosanna Therapeutics has announced its launch with a significant investment of $80 million. The funding aims to support the development and commercialization of a new nighttime nasal spray designed to treat obstructive sleep apnea. The lead investor, Broadview Ventures, is a prominent player in the healthcare and life sciences sectors known for supporting innovative approaches in medical treatments. This project seeks to address a critical unmet medical need and enhance the quality of life for individuals suffering from obstructive sleep apnea, a condition associated with serious health risks if left untreated.
Sectors
- Healthcare
- Venture Capital
Geography
- United States – Broadview Ventures, the leading investor, is based in the United States, which often drives healthcare innovations globally.
Industry
- Healthcare – The article pertains to the development of a new medical treatment for obstructive sleep apnea, a significant health condition.
- Venture Capital – Due to Broadview Ventures' involvement, the article also relates to the venture capital industry, which funds innovative healthcare solutions.
Financials
- $80 Million – The total funding amount received by Mosanna Therapeutics to develop a new nasal spray for obstructive sleep apnea.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Mosanna Therapeutics | Target | Company | A company focused on developing novel treatments for obstructive sleep apnea. |
| Broadview Ventures | Investor | Company | A venture capital firm investing in innovative healthcare and life sciences solutions. |